ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

Phase 4

Completed

Conditions: Skin Aging

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2009-03-05

Last Posted Date: 2019-01-29

Lead Sponsor: Allergan

Target Recruit Count: 45

Registration Number: NCT00856414

CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy

Completed

Conditions: Cervical Dystonia

Interventions: Other: No Intervention

First Posted Date: 2009-02-04

Last Posted Date: 2014-07-17

Lead Sponsor: Allergan

Target Recruit Count: 1046

Registration Number: NCT00836017

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Completed

Conditions: Ocular Hypertension

Interventions: Drug: Loteprednol etabonate ophthalmic suspension 0.5%
Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).

First Posted Date: 2009-02-03

Last Posted Date: 2011-09-26

Lead Sponsor: Allergan

Target Recruit Count: 50

Registration Number: NCT00834171

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone
Drug: Tazarotene

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00834210

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone; Tretinoin
Drug: Tretinoin

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 163

Registration Number: NCT00835198

A Natural History Study of Patients With Dry Eye

Completed

Conditions: Dry Eye

Interventions: Other: Artificial Tears

First Posted Date: 2009-02-02

Last Posted Date: 2017-07-25

Lead Sponsor: Allergan

Target Recruit Count: 284

Registration Number: NCT00833235

Locations: 🇺🇸
Jones Eye Institute, Little Rock, Arkansas, United States
🇺🇸
North Valley Eye Medical Group, Inc., Mission Hills, California, United States
🇺🇸
Eye Center of Northern Colorado, Fort Collins, Colorado, United States

and more 14 locations

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

Phase 4

Terminated

Conditions: Acne Vulgaris

Interventions: Drug: Tazarotene Cream 0.1%
Drug: Adapalene

First Posted Date: 2009-01-26

Last Posted Date: 2012-09-12

Lead Sponsor: Allergan

Target Recruit Count: 165

Registration Number: NCT00829049

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Cyclosporine Ophthalmic Emulsion 0.05%

First Posted Date: 2009-01-22

Last Posted Date: 2019-04-25

Lead Sponsor: Allergan

Target Recruit Count: 35

Registration Number: NCT00827255

Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination
Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy

First Posted Date: 2009-01-14

Last Posted Date: 2009-01-14

Lead Sponsor: Allergan

Target Recruit Count: 140

Registration Number: NCT00822055

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Drug: latanoprost 0.005%

First Posted Date: 2008-12-19

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 148

Registration Number: NCT00811564

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy